PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31830506-4 2020 We demonstrated that ANGII induces a significant reduction in expression of TfR1, Fpn1, IRP2 proteins and Nrf2 mRNA and an increase in ferritin protein and hepcidin mRNA, while candesartan, but not PD123319, significantly attenuated or reversed all these ANGII-induced changes in Neuro-2a cells. candesartan 177-188 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 21-26 29158353-6 2018 The hypertensive effect of BP1 expression is prevented by candesartan, an angiotensin II (AngII) receptor antagonist, or by tempol, an inhibitor of reactive oxygen species. candesartan 58-69 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 90-95 27210827-7 2016 Furthermore, only Olmesartan and Candesartan could downregulate the ACE-AngII-AT1 axis and upregulate the ACE2-Ang(1-7)-Mas axis in vitro. candesartan 33-44 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 72-77 28919108-8 2017 In addition, Ang II treatment enhanced lipopolysaccharide-induced production of monocyte chemoattractant protein 1 in astrocytes, and pretreatment with candesartan or SN50, an NF-kappaB inhibitor, suppressed the effects of Ang II. candesartan 152-163 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 223-229 27210827-3 2016 We designed this study to examine and compare the effects of several ARBs widely used in clinics, including Olmesartan, Candesartan, Telmisartan, Losartan, Valsartan and Irbesartan, on the ACE-AngII-AT1 axis and the ACE2-Ang(1-7)-Mas axis during the development of cardiac remodeling after pressure overload. candesartan 120-131 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 193-198 28993503-7 2018 Treatment with candesartan during Ang II-induced hypertension attenuated kidney disease development in MYH9E1841K/E1841K mice. candesartan 15-26 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 34-40 28882562-0 2017 Candesartan prevents resiniferatoxin-induced sensory small-fiber neuropathy in mice by promoting angiotensin II-mediated AT2 receptor stimulation. candesartan 0-11 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 97-111 28882562-8 2017 Thus, candesartan may promote AT2R activation by blocking AT1R and increasing Ang II production and enhance its mechanisms of neuroprotection in our RTX model. candesartan 6-17 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 78-84 27447725-3 2016 Ang II stimulated glucagon-like peptide-1 and PYY release from primary cultures of mouse and human colon, which was antagonized by the specific Ang II type 1 receptor blocker candesartan. candesartan 175-186 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 0-6 27447725-3 2016 Ang II stimulated glucagon-like peptide-1 and PYY release from primary cultures of mouse and human colon, which was antagonized by the specific Ang II type 1 receptor blocker candesartan. candesartan 175-186 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 144-150 27447725-5 2016 In Ussing chamber recordings, Ang II reduced short circuit currents in mouse distal colon preparations, which was antagonized by candesartan or a specific neuropeptide Y1 receptor inhibitor but insensitive to amiloride. candesartan 129-140 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 30-36 27210827-8 2016 Our data suggest that Olmesartan, Candesartan and Losartan could effectively inhibit pressure overload-induced cardiac remodeling even when with knockdown of Ang II, possibly through upregulation of the expression of the ACE2-Ang(1-7)-Mas axis and downregulation of the expression of the ACE-AngII-AT1 axis. candesartan 34-45 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 158-164 27210827-8 2016 Our data suggest that Olmesartan, Candesartan and Losartan could effectively inhibit pressure overload-induced cardiac remodeling even when with knockdown of Ang II, possibly through upregulation of the expression of the ACE2-Ang(1-7)-Mas axis and downregulation of the expression of the ACE-AngII-AT1 axis. candesartan 34-45 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 292-297 22892395-0 2012 Candesartan, an angiotensin II AT1-receptor blocker and PPAR-gamma agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. candesartan 0-11 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 16-30 26876143-8 2016 The ATr1 blocker, candesartan prevented the positive chronotropic effects of AngII. candesartan 18-29 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 77-82 23575826-5 2013 These effects of AngII on nerve responses were blocked by the angiotensin II type 1 receptor (AT1) antagonist CV11974. candesartan 110-117 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 17-22 20944638-6 2010 Furthermore, in angiotensinogen-knockout mice lacking endogenous AngII, TAC-induced cardiac hypertrophy was regressed by Candesartan, Olmesartan and Losartan but not by Telmisartan and Valsartan administration. candesartan 121-132 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 65-70 22493070-7 2012 Ang II effects were blunted by an Ang II type 1 receptor antagonist (candesartan) and inhibitors of calcineurin (cyclosporine A and FK506) and nuclear factor of activated T-cells (VIVIT). candesartan 69-80 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 0-6 22493070-7 2012 Ang II effects were blunted by an Ang II type 1 receptor antagonist (candesartan) and inhibitors of calcineurin (cyclosporine A and FK506) and nuclear factor of activated T-cells (VIVIT). candesartan 69-80 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 34-40 22405822-4 2012 Pretreatment of the cells with either candesartan (a selective Ang II type 1 receptor [AT(1)R] antagonist) or Tempol (a cell-permeable superoxide scavenger) significantly inhibited Ang II-induced DNA synthesis. candesartan 38-49 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 63-69 22405822-4 2012 Pretreatment of the cells with either candesartan (a selective Ang II type 1 receptor [AT(1)R] antagonist) or Tempol (a cell-permeable superoxide scavenger) significantly inhibited Ang II-induced DNA synthesis. candesartan 38-49 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 181-187 22405822-6 2012 Pretreatment with candesartan significantly inhibited Ang II- induced JAK/STAT3 phosphorylation. candesartan 18-29 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 54-60 22405822-9 2012 Pretreatment of the cells with both candesartan and SB203580 (a p38 MAPK inhibitor) significantly inhibited the Ang II- induced increase in Flk-1 expression. candesartan 36-47 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 112-118 22234465-5 2012 These effects were completely blocked by the Ang II type I receptor antagonist candesartan or deletion of Ang II type 1a receptor. candesartan 79-90 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 45-51 22289845-7 2012 These effects of Ang II are blocked by the specific Ang II AT(1) receptor (AT(1)R) antagonist candesartan, but not by the AT(2) receptor (AT(2)R) antagonist PD123319. candesartan 94-105 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 17-23 22289845-7 2012 These effects of Ang II are blocked by the specific Ang II AT(1) receptor (AT(1)R) antagonist candesartan, but not by the AT(2) receptor (AT(2)R) antagonist PD123319. candesartan 94-105 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 52-58 17220190-7 2007 The AT(1) receptor antagonist candesartan and losartan as well as diphenyleneiodonium, an inhibitor of flavoproteins including NAD(P)H oxidase, significantly reduced the platelet-leukocyte-endothelial cell interactions elicited by either ANG II administration or BCCAO/reperfusion. candesartan 30-41 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 238-244 19907343-7 2010 In wild-type mice, Ang IV and Ang II induced dose-dependent pressor and renal vasoconstrictor responses, which were antagonized by the AT1 receptor blocker candesartan. candesartan 156-167 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 30-36 16332932-7 2006 ANG II-induced constrictions were eliminated by AT(1) receptor blockade with 4 microM candesartan. candesartan 86-97 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 0-6 17587756-9 2007 Moreover, candesartan directly inhibited Ang II-mediated induction of CTGF in cultured cardiac fibroblasts. candesartan 10-21 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 41-47 12657564-10 2003 These effects of ANG II on UB branching are abrogated by pretreatment with the AT1 receptor antagonist candesartan. candesartan 103-114 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 17-23 16385086-9 2006 Ang II-induced TXB2 upregulation was reduced by cotreatment with Ang II type I receptor antagonist (candesartan, 20 mg/kg per day). candesartan 100-111 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 0-6 16385086-9 2006 Ang II-induced TXB2 upregulation was reduced by cotreatment with Ang II type I receptor antagonist (candesartan, 20 mg/kg per day). candesartan 100-111 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 65-71 15699040-5 2005 Similarly, incubation of cultured cardiomyocytes with AngII increased CTGF mRNA expression by 2-fold, which was blocked by candesartan and a general PKC inhibitor, GF109203X. candesartan 123-134 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 54-59 10988260-7 2000 This effect of Ang II was inhibited by AT1-receptor antagonism (candesartan) and blockade of the MAPK/ERK cascade (PD98059); in contrast, inhibition of the P38 kinase pathway (SB202190) and blockade of the release of the transcription factor NFkappaB (PDTC) did not have any effect in the Ang II-induced activation of the collagen I gene. candesartan 64-75 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 15-21 12623988-5 2003 The Ang II-dependent repression of Npr1 promoter activity was partially blocked by both angiotensin type 1 and type 2 antagonists candesartan and PD 123,319, respectively. candesartan 130-141 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 4-10 11729239-7 2001 The AngII-induced effect on procol alpha 2(I) was completely inhibited by candesartan (AngII type 1 receptor antagonist) and substantially blunted by bosentan (dual ET receptor antagonist) (P < 0.01), whereas the ET-induced activation of collagen I gene was blocked only by bosentan. candesartan 74-85 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 4-9 11729239-7 2001 The AngII-induced effect on procol alpha 2(I) was completely inhibited by candesartan (AngII type 1 receptor antagonist) and substantially blunted by bosentan (dual ET receptor antagonist) (P < 0.01), whereas the ET-induced activation of collagen I gene was blocked only by bosentan. candesartan 74-85 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 87-92 28095236-2 2001 Injections of Ang II caused dose-related increases in systemic arterial pressure that were antagonised by candesartan. candesartan 106-117 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 14-20 12429556-9 2003 AAD and EAD reductions in ANG II were blocked by 1 microM candesartan. candesartan 58-69 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 26-32 9892148-0 1999 Effects of candesartan and PD123319 on responses to angiotensin II in the anesthetized mouse. candesartan 11-22 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 52-66 9892148-5 1999 Pressor responses to AngII were attenuated by candesartan but were not altered by PD123319. candesartan 46-57 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 21-26 9196031-5 1997 CV-11974 failed to suppress the stretch-induced activation of MAP kinases in Agt-/- cardiac myocytes while it inhibited the activation in Agt+/+ cardiac myocytes. candesartan 0-8 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 138-141 34439486-6 2021 The Ang II type 1 receptor (AT1R) blocker, candesartan, and the ROS scavenger, Tiron, prevented Ang II-induced endothelial dysfunction. candesartan 43-54 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 96-102